Displaying items by tag: FDA

Moderna, Inc., a biotechnology company pioneering messenger ARN (ARNm), therapeutics and vaccines, received emergency use authorization (EUA) from the Food and Drug Administration (FDA) for its bivalent Covid-19 mRNA-1273.222 booster vaccine intended to protect against BA.4/BA.5 variant omicron in children aged 6 months to 5 years.

Published in Experts
Tagged under

Moderna, Inc, a biotechnology company pioneering messenger ARN (ARNm), therapeutics and vaccines, announced today that it received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its bivalent COVID-19 booster vaccine targeting omicron BA.4/BA, 5, mRNA-1273.222, for children and adolescents 6 to 17 years of age.

Published in Experts
Tagged under